In this issue:
Ribociclib + endocrine therapy in advanced breast cancer
Low-dose tamoxifen in breast intraepithelial neoplasia
Concurrent NCT & oestrogen deprivation in ER+, HER2– disease
Language and later stage breast cancer
Uptake of cancer risk-reduction options among BRCA mutation carriers
Serum thymidine kinase 1: a potential circulating prognostic marker
Assessing Ki67 response after shortterm endocrine treatment
Predicting response to chemotherapy-free HER2-targeted treatments
Predicting recurrence with EndoPredict in ER+, HER2– disease
Preliminary data from the ongoing phase IIIb PERUSE trial
Please login below to download this issue (PDF)